Corrigendum to "Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*" [Eur J Cancer 91 (2018) 116-124]

Affiliations

• ¹ The Christie NHS Foundation Trust, University of Manchester, Manchester, UK; CRUK Manchester Institute, Manchester, UK.
• ² Melanoma Institute Australia and the University of Sydney, Sydney, NSW, Australia; Westmead and Blacktown Hospitals, Westmead, Australia.
• ³ University Hospital of Zurich, Zurich, Switzerland.
• ⁴ Massachusetts General Hospital, Cancer Center, Boston, MA, USA.
• ⁵ Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia.
• ⁶ University Hospital Essen, Essen and German Cancer Consortium, Germany.
• ⁷ Schleswig-Holstein University Hospital, Kiel, Germany.
• ⁸ Melanoma Institute Australia and the University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Australia.
• ⁹ Hospital Clínic de Barcelona, Barcelona, Spain.
• ¹⁰ Istituto Nazionale Tumori "Fondazione G. Pascale"-IRCCS, Naples, Italy.
• ¹¹ Medical Oncology and Immunotherapy University Hospital of Siena, Siena, Italy.
• ¹² IRCCS e IRST (Istituto Scientifico Romagnolo per Lo Studio e La Cura Dei Tumori), Meldola, Italy.
• ¹³ The Royal Marsden NHS Foundation Trust, London, UK.
• ¹⁴ Melanoma Institute Australia and the University of Sydney, Sydney, NSW, Australia.
• ¹⁵ The Christie NHS Foundation Trust, University of Manchester, Manchester, UK. Electronic address: paul.lorigan@christie.nhs.uk.